AIMS: To determine whether recurrent disc hemorrhage (DH) accelerates glaucomatous visual field (VF) loss compared to an isolated, single, detected DH. METHODS: We evaluated the disc photographs of consecutive patients with >/=5 SITA-Standard fields for DH. Group A had patients with a single DH in one eye, and group B had at least one recurrence in the same eye. Automated pointwise linear regression analysis was used to calculate rates of progression. Logistic regression was used to determine ocular or systemic variables associated with DH recurrence after baseline assessment. RESULTS: One hundred and seventeen patients were enrolled (group A = 72, group B = 45). The mean age was 67.1 +/- 10.8 years; most patients were women (65%) of European ancestry (92%) diagnosed with primary open-angle glaucoma (47%). The mean number of VF after the initial DH was 7.9 +/- 2.9, spanning a mean of 4.6 +/- 2.2 years. None of the ocular or systemic characteristics revealed a significant difference between groups. The mean global rate of progression (group A, -0.8 +/- 0.6 vs group B, -0.8 +/- 0.7 dB/year, p = 0.93) and number of eyes reaching a progression endpoint (group A, 70% vs group B, 73%, p = 0.80) did not differ between groups. Recurrent DH eyes showed a tendency to be followed longer, with a greater number of disc photographs, which was not significant in the multivariate analysis. The global rates of progression between groups remained non-significant even after adjusting to follow-up time and number of VF tests (p = 0.69). CONCLUSION: Recurrent DH does not result in a faster rate of VF progression compared to a single detected DH. Eyes with single or recurrent DH have similar risks for future disease progression.
AIMS: To determine whether recurrent disc hemorrhage (DH) accelerates glaucomatous visual field (VF) loss compared to an isolated, single, detected DH. METHODS: We evaluated the disc photographs of consecutive patients with >/=5 SITA-Standard fields for DH. Group A had patients with a single DH in one eye, and group B had at least one recurrence in the same eye. Automated pointwise linear regression analysis was used to calculate rates of progression. Logistic regression was used to determine ocular or systemic variables associated with DH recurrence after baseline assessment. RESULTS: One hundred and seventeen patients were enrolled (group A = 72, group B = 45). The mean age was 67.1 +/- 10.8 years; most patients were women (65%) of European ancestry (92%) diagnosed with primary open-angle glaucoma (47%). The mean number of VF after the initial DH was 7.9 +/- 2.9, spanning a mean of 4.6 +/- 2.2 years. None of the ocular or systemic characteristics revealed a significant difference between groups. The mean global rate of progression (group A, -0.8 +/- 0.6 vs group B, -0.8 +/- 0.7 dB/year, p = 0.93) and number of eyes reaching a progression endpoint (group A, 70% vs group B, 73%, p = 0.80) did not differ between groups. Recurrent DH eyes showed a tendency to be followed longer, with a greater number of disc photographs, which was not significant in the multivariate analysis. The global rates of progression between groups remained non-significant even after adjusting to follow-up time and number of VF tests (p = 0.69). CONCLUSION: Recurrent DH does not result in a faster rate of VF progression compared to a single detected DH. Eyes with single or recurrent DH have similar risks for future disease progression.
Authors: Donald L Budenz; Douglas R Anderson; William J Feuer; Julia A Beiser; Joyce Schiffman; Richard K Parrish; Jody R Piltz-Seymour; Mae O Gordon; Michael A Kass Journal: Ophthalmology Date: 2006-09-25 Impact factor: 12.079
Authors: Kouros Nouri-Mahdavi; Douglas Hoffman; Douglas Gaasterland; Joseph Caprioli Journal: Invest Ophthalmol Vis Sci Date: 2004-12 Impact factor: 4.799
Authors: Catherine Boden; Eytan Z Blumenthal; John Pascual; Gavin McEwan; Robert N Weinreb; Felipe Medeiros; Pamela A Sample Journal: Am J Ophthalmol Date: 2004-12 Impact factor: 5.258
Authors: Robert Laemmer; Thu K Nguyen; Folkert K Horn; Christian Y Mardin Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-08-10 Impact factor: 3.117
Authors: Huiyuan Hou; Sasan Moghimi; Linda M Zangwill; James A Proudfoot; Tadamichi Akagi; Takuhei Shoji; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Ophthalmol Glaucoma Date: 2019-11-14
Authors: Dong An; Philip House; Christopher Barry; Andrew Turpin; Allison M McKendrick; Balwantray C Chauhan; Siobhan Manners; Stuart L Graham; Dao-Yi Yu; William H Morgan Journal: PLoS One Date: 2017-07-28 Impact factor: 3.240